{"id":"nct:NCT05869903","kind":"trial","title":"A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","authors":["Eli Lilly and Company"],"author_count":1,"year":2023,"published":"2023-05-22","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05869903","source_url":"https://clinicaltrials.gov/study/NCT05869903","archive_url":"https://space-kitty.com/papers/nct:NCT05869903","updated":"2026-08-14","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Obesity","Overweight","Overweight or Obesity"],"details":{"acronym":"ATTAIN-1","status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":3127,"sponsor":"Eli Lilly and Company","conditions":["Obesity","Overweight","Overweight or Obesity"],"interventions":["DRUG: Orforglipron","DRUG: Placebo"],"start_date":"2023-06-05","start_date_type":"ACTUAL","primary_completion_date":"2025-07-25","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}